Comparative Pharmacology
Head-to-head clinical analysis: INREBIC versus XELJANZ.
Peer-Reviewed Evidence
Head-to-head clinical analysis: INREBIC versus XELJANZ.
INREBIC vs XELJANZ
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fedratinib is a selective Janus kinase 2 (JAK2) inhibitor. It inhibits JAK2 and its mutant forms, including JAK2V617F, leading to reduced phosphorylation of signal transducer and activator of transcription (STAT) proteins and decreased proliferation of abnormal hematopoietic cells.
Janus kinase (JAK) inhibitor. Selectively inhibits JAK1 and JAK3, mediating signaling of cytokines/growth factors involved in immune response and hematopoiesis.
100 mg orally twice daily continuously until disease progression or unacceptable toxicity.
5 mg orally twice daily; for rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis. For ulcerative colitis induction, 10 mg orally twice daily for 8 weeks; maintenance at 5 mg orally twice daily.
None Documented
None Documented
Terminal elimination half-life approximately 14 hours; supports twice-daily dosing for steady-state attainment within 3 days
Terminal half-life is approximately 3.3 hours. Twice-daily dosing maintains therapeutic concentrations.
Fecal (77.6% as metabolites, 2.2% as unchanged drug); renal (8.5% as metabolites, <1% as unchanged drug)
Approximately 70% of the dose is excreted in urine (30% as unchanged drug, 40% as metabolites) and 20% in feces (10% as unchanged drug).
Category C
Category C
JAK Inhibitor
JAK Inhibitor